ArticleFrontiers in oncology2024

Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation.

Xiaolin Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.